BMY 14802

Cat. No.:	HY-153091
CAS No.:	105565-56-8
Molecular Formula:	$C_{18}H_{22}F_2N_4O$
Molecular Weight:	348.39
Target:	Adrenergic Receptor; 5-HT Receptor; Sigma Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (143.52 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.8703 mL	14.3517 mL	28.7035 mL
	5 mM	0.5741 mL	2.8703 mL	5.7407 mL
	10 mM	0.2870 mL	1.4352 mL	2.8703 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 1.67 mg/mL (4.79 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

BMY 14802 is a sigma-1 receptor (σ1R) antagonist, as well as an agonist at serotonin (5-HT) 1A and adrenergic alpha-1 receptors. BMY 14802 inhibits abnormal involuntary movement (AIM) in rat Parkinson's disease (PD) model, with down-regulating the expression of AIM[1][2].

IC_{50} & Target			
	Sigma 1 Receptor	5-HT_{1A} Receptor	α1-adrenergic receptor

In Vivo

BMY 14802 (15 mg/kg; i.p.; single dose) significantly inhibits AIM and decreases dyskinesias, especially in the first hour in rat PD model[1][2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Paquette MA, et al. The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism. Psychopharmacology (Berl). 2009 Jul;204(4):743-54.

[2]. Paquette MA, et al. Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias. Neuroreport. 2008 Jan 8;19(1):111-5.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA